

stated above and submit 8 true paper copies to the Office of the Secretary by noon the next day pursuant to Commission Rule 210.4(f), 19 CFR 210.4(f). Submissions should refer to the investigation number (“Inv. No. 1098”) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, https://www.usitc.gov/secretary/documents/handbook_on_filing_procedures.pdf). Persons with questions regarding filing should contact the Secretary, (202) 205–2000.

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) by the

Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: July 24, 2019.

Katherine Hiner,

Supervisory Attorney.

[FR Doc. 2019–16151 Filed 7–29–19; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 30, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on May 15, 2019, Chemtos, LLC, 16713 Picadilly Court, Round Rock, Texas 78664–8544 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
3-Fluoro-N-methylcathinone (3-FMC)	1233	
Cathinone	1235	
Methcathinone	1237	
4-Fluoro-N-methylcathinone (4-FMC)	1238	
Pentedrone (α-methylaminovalephorphenone)	1246	
Mephedrone (4-Methyl-N-methylcathinone)	1248	
4-Methyl-N-ethylcathinone (4-MEC)	1249	
Naphyrone	1258	
N-Ethylamphetamine	1475	
N,N-Dimethylamphetamine	1480	
Fenethylamine	1503	
Aminorex	1585	
4-Methylaminorex (cis isomer)	1590	
Gamma Hydroxybutyric Acid	2010	
Methaqualone	2565	
Mecloqualone	2572	
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole)	6250	
SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole)	7008	
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7010	
5-Fluoro-UR–144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	7011	
AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7012	
JWH–019 (1-Hexyl-3-(1-naphthyl)indole)	7019	
MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7020	
AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7023	
THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone	7024	
AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7031	
MAB–CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7032	
5F–AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)	7033	
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7034	
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7035	
MDMB–CHMICA, MMB–CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)	7042	
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide	7048	
5F–APINACA, 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)	7049	
JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthyl) indole)	7081	
SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole)	7104	
JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthyl)indole)	7118	
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthyl) indole)	7122	

Controlled substance	Drug code	Schedule
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	7144	
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)	7173	
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	7200	
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole)	7201	
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole)	7203	
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate)	7222	
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate)	7225	
Alpha-ethyltryptamine	7249	
Ibogaine	7260	
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol)	7297	
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol)	7298	
Lysergic acid diethylamide	7315	
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)	7348	
Marihuana Extract	7350	
Marihuana	7360	
Parahexyl	7374	
Mescaline	7381	
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2)	7385	
3,4,5-Trimethoxyamphetamine	7390	
4-Bromo-2,5-dimethoxyamphetamine	7391	
4-Bromo-2,5-dimethoxyphenethylamine	7392	
4-Methyl-2,5-dimethoxyamphetamine	7395	
2,5-Dimethoxyamphetamine	7396	
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole)	7398	
2,5-Dimethoxy-4-ethylamphetamine	7399	
3,4-Methylenedioxyamphetamine	7400	
5-Methoxy-3,4-methylenedioxyamphetamine	7401	
N-Hydroxy-3,4-methylenedioxyamphetamine	7402	
3,4-Methylenedioxy-N-ethylamphetamine	7404	
3,4-Methylenedioxymethamphetamine	7405	
4-Methoxyamphetamine	7411	
5-Methoxy-N-N-dimethyltryptamine	7431	
Alpha-methyltryptamine	7432	
Bufotenine	7433	
Diethyltryptamine	7434	
Dimethyltryptamine	7435	
Psilocybin	7437	
Psilocyn	7438	
5-Methoxy-N,N-diisopropyltryptamine	7439	
N-Ethyl-1-phenylcyclohexylamine	7455	
1-(1-Phenylcyclohexyl)pyrrolidine	7458	
1-[1-(2-Thienyl)cyclohexyl]piperidine	7470	
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	7473	
N-Ethyl-3-piperidyl benzilate	7482	
N-Methyl-3-piperidyl benzilate	7484	
N-Benzylpiperazine	7493	
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)	7498	
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E)	7509	
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	
2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)	7518	
2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	
2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N)	7521	
2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4)	7532	
MDPV (3,4-Methylenedioxypropylvalerone)	7535	
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe)	7536	
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)	7537	
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)	7538	
Methylone (3,4-Methylenedioxy-N-methylcathinone)	7540	
Butylone	7541	
Pentylone	7542	
alpha-pyrrolidinopentiophenone (α -PVP)	7545	
alpha-pyrrolidinobutiophenone (α -PBP)	7546	
AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole)	7694	
Acetyldihydrocodeine	9051	
Benzylmorphine	9052	
Codeine-N-oxide	9053	
Cyprenorphine	9054	
Desomorphine	9055	
Etorphine (except HCl)	9056	
Codeine methylbromide	9070	
Dihydromorphine	9145	
Difenoxin	9168	

Controlled substance	Drug code	Schedule
Heroin	9200	
Hydromorphenol	9301	
Methyldesorphine	9302	
Methyldihydromorphenol	9304	
Morphine methylbromide	9305	
Morphine methylsulfonate	9306	
Morphine-N-oxide	9307	
Myrophine	9308	
Nicocodeine	9309	
Nicomorphine	9312	
Normorphine	9313	
Pholcodine	9314	
Thebacon	9315	
Acetorphine	9319	
Drotebanol	9335	
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)	9547	
AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)	9551	
Acetylmethadol	9601	
Allylprodine	9602	
Alphacetylmethadol except levo-alphacetylmethadol	9603	
Alphameprodine	9604	
Alphamethadol	9605	
Benzethidine	9606	
Betacetylmethadol	9607	
Betameprodine	9608	
Betamethadol	9609	
Betaprodine	9611	
Clonitazene	9612	
Dextromoramide	9613	
Diampromide	9615	
Diethylthiambutene	9616	
Dimenoxadol	9617	
Dimepheptanol	9618	
Dimethylthiambutene	9619	
Dioxaphetyl butyrate	9621	
Dipipanone	9622	
Ethylmethylthiambutene	9623	
Etonitazene	9624	
Etoxidine	9625	
Furethidine	9626	
Hydroxypethidine	9627	
Ketobemidone	9628	
Levomoramide	9629	
Levophenacetylmorphan	9631	
Morpheridine	9632	
Noracetylmethadol	9633	
Norlevorphanol	9634	
Normethadone	9635	
Norpipanone	9636	
Phenadoxone	9637	
Phenampramide	9638	
Phenoperidine	9641	
Piritramide	9642	
Proheptazine	9643	
Propoperidine	9644	
Racemoramide	9645	
Trimeperidine	9646	
Phenomorphane	9647	
Propiram	9649	
1-Methyl-4-phenyl-4-propionoxypiperidine	9661	
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	9663	
Tilidine	9750	
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide)	9811	
Para-Fluorofentanyl	9812	
3-Methylfentanyl	9813	
Alpha-methylfentanyl	9814	
Acetyl-alpha-methylfentanyl	9815	
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9821	
Butyryl Fentanyl	9822	
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)	9824	
Beta-hydroxyfentanyl	9830	
Beta-hydroxy-3-methylfentanyl	9831	
Alpha-methylthiofentanyl	9832	
3-Methylthiofentanyl	9833	

Controlled substance	Drug code	Schedule
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)	9834	I
Thiofentanyl	9835	I
Beta-hydroxythiofentanyl	9836	I
Amphetamine	1100	II
Methamphetamine	1105	II
Lisdexamfetamine	1205	II
Phenmetrazine	1631	II
Methylphenidate	1724	II
Amobarbital	2125	II
Pentobarbital	2270	II
Secobarbital	2315	II
Glutethimide	2550	II
Nabilone	7379	II
1-Phenylcyclohexylamine	7460	II
Phencyclidine	7471	II
4-Anilino-N-phenethyl-4-piperidine (ANPP)	8333	II
Phenylacetone	8501	II
1-Piperidinocyclohexanecarbonitrile	8603	II
Alphaprodine	9010	II
Anileridine	9020	II
Cocaine	9041	II
Codeine	9050	II
Etorphine HCl	9059	II
Dihydrocodeine	9120	II
Oxycodone	9143	II
Hydromorphone	9150	II
Diphenoxylate	9170	II
Ecgonine	9180	II
Ethylmorphine	9190	II
Hydrocodone	9193	II
Levomethorphan	9210	II
Levorphanol	9220	II
Isomethadone	9226	II
Meperidine	9230	II
Meperidine intermediate-A	9232	II
Meperidine intermediate-B	9233	II
Meperidine intermediate-C	9234	II
Methadone	9250	II
Methadone intermediate	9254	II
Metopon	9260	II
Dextropropoxyphene, bulk (non-dosage forms)	9273	II
Morphine	9300	II
Thebaine	9333	II
Dihydroetorphine	9334	II
Levo-alphaacetylmethadol	9648	II
Oxymorphone	9652	II
Noroxymorphone	9668	II
Phenazocine	9715	II
Thiafentanil	9729	II
Piminodine	9730	II
Racemethorphan	9732	II
Racemorphan	9733	II
Alfentanil	9737	II
Remifentanil	9739	II
Sufentanil	9740	II
Carfentanil	9743	II
Tapentadol	9780	II
Bezitramide	9800	II
Fentanyl	9801	II
Moramide-intermediate	9802	II

The company plans to manufacture small quantities of the listed controlled substances in bulk for distribution to its customers.

Dated: July 16, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019-16176 Filed 7-29-19; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Application: Alcami Carolinas Corporation

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 29, 2019. Such persons may also file a written request for a hearing on the application on or before August 29, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia

22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 8, 2019, Alcami Carolinas Corporation, 1726 North 23rd Street, Wilmington, North Carolina 28405 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Psilocybin	7437	I
Psilocyn	7438	I
Thebaine	9333	II
Pentobarbital	2270	II

The company plans to import the listed controlled substances in bulk for the manufacturing of capsules/tablets for Phase II clinical trials. Approval of permit applications will occur only when the registrant's activity is consistent with what is authorized

under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: July 16, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019-16164 Filed 7-29-19; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: The registrant listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as an importer of schedule I or schedule II controlled substances.

SUPPLEMENTARY INFORMATION:

The company listed below applied to be registered as an importer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for a hearing were submitted for this notice.

Company	FR docket	Published
AndersonBrecon, Inc	84 FR 21813	May 15, 2019.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I controlled substances to the above listed company.

Dated: July 16, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019-16169 Filed 7-29-19; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Application: Research Triangle Institute

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 29, 2019. Such persons may also file a written request for a

hearing on the application on or before August 29, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.34(a), this is notice that on May 03, 2019, Research Triangle Institute, 3040 East Cornwallis Road, Hermann